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Background. Inhalation of thermal water has been used empirically in the treatment of chronic diseases of upper and lower
respiratory tract. This study investigates biomarkers of eﬀect in exhaled breath (nitric oxide (NO)) and in exhaled breath
condensate (EBC) (hydrogen peroxide (H2O2), anions, toxic heavy metals of tobacco smoke) for patients with lung diseases
inhaling salt-bromide-iodine thermal water. Methods. This study enrolled two groups of patients, twenty with alveolar pulmonary
diseases—pneumoconiosis—twenty-two with bronchial diseases. Patients received 12 days inhalation treatment with thermal
water in Terme of Monticelli (Parma), Italy. Results. No statistically significant diﬀerences were found for NO at diﬀerent flow
rates in both groups of patients before and after thermal water inhalation. Also in EBC no statistically significant diﬀerences were
present for H2O2 concentrations, toxic heavy metals concentrations, and anion concentrations before and after treatment. Nitrates
in EBC were found to be significantly higher in patients before inhalation than in controls as well as in patients after inhalation
versus controls. Conclusions. This study contributes to better quantify functional and biochemical changes in airways before and
after thermal water treatment.
1. Introduction
The treatment of diseases with thermal water belongs to the
oldest medical therapies. Waters and their components were
used as therapeutic agents from the nineteenth century to the
present day especially for lung diseases. The most frequently
used therapies based on mineral waters were drinking,
bath, and inhalation cures. The positive influence of these
cures on the recovery of the patients was attributed to the
physicochemical properties of the water. Particulary, some
studies show that sulphurous thermal water inhalation has
mucolitic, antioxidant, and antielastase activity [1] that may
help to control airway inflammation at the upper alveolar or
lower bronchial level [2, 3]. The possible benefit of thermal
sulphurous water inhalation could be attributed to the
presence of hydrogen sulphide (H2S). In the past, hydrogen
sulphide was considered only a toxic gas. Recent studies
indicate that it is also produced at significant amounts
(50 μM) in most tissues and exerts many physiological eﬀects
suggesting its potential role as a regulatory mediator such as
monoxide oxide (CO) or nitric oxide (NO) [4]. Moreover,
inhaling treatments can be done with salt-bromide-iodine
thermal waters of natural springs. Many scientists think
that particular composition of this thermal water plays a
useful anti-inflammatory and sedative purifying action on
the mucous membranes of the respiratory apparatus: aerosol
tiny particels are vaporized and inhaled by the subjects,
pass through respiratory tract, giving relief to nose, throat,
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bronchus, lungs, and larynx. In the literature there are only
few works that study the eﬀect of inhalation of salt-bromide-
iodine thermal water on airway inflammation in patients
with lung diseases such as chronic obstructive pulmonary
disease (COPD) [5, 6]. Moreover, despite its widespread
use, much uncertainty exists about the indications and
therapeutic mechanisms of thermal water inhalations in the
treatment of respiratory diseases. Particularly, H2S is a strong
reducing agent, that is present in salt-bromide-iodine water
at lower concentration compared to sulphurous thermal,
therefore, it has been suggested that some of its benefit eﬀects
may be mediated by protection of protein thiol groups from
oxidation. Additional mechanism through which H2S and
other salts may exert antioxidant eﬀect involves stimulation
of cysteine transport to the cells and enhancement of
glutathione synthesis [7]. Molecules bearing SH groups,
such as gluthatione (GSH), play a fundamental role in the
defensive system of human airways: GSH concentrations
(200–400 μM) in the epithelial lining fluid (ELF) of the lungs
are approximately 100 times higher than that of plasma (2–
4 μM). Lung extracellular ELF is rich in the antioxidant GSH,
which detoxifies oxidants, free radicals, and electrophilic
compounds such as ions of heavy metals contained in
cigarette smoke: lead (Pb), cadmium (Cd), and cobalt (Co)
[8]. The aim of this study was to investigate and to quantify
the eﬀects of salt-bromide-iodine thermal water inhalation
on lung function parameters and on biomarkers detected in
biological matrices, collected noninvasively (exhaled breath
and exhaled breath condensate (EBC)). The assessment of
inflammatory in exhaled air was evaluated with fractional
exhaled nitric oxide (FENO) [9, 10]. In order to evaluate
the eﬀect of thermal treatment on EBC anions concentration
and to compare it with EBC sample controls, we quantified
six anions (formate, chloride, nitrite, nitrate, sulphate, and
oxalate) before and after inhalation of thermal salt-bromide-
iodine thermal water in patients with respiratory diseases.
2. Materials andMethods
2.1. Study Design. The design of the present study was
focused on two groups of patients with pneumoconiosis
and with bronchial diseases inhaling salt-bromide-iodine
thermal water in Terme of Monticelli (Parma), Italy. This
thermal water is classified as medium-mineral and contains
bromide, iodide, hydrogen sulphide, and sulphates, springs
forth at temperature of 13◦C, and is used in treatment of
diﬀerent respiratory diseases. The aerosol was administrated
daily for 12 consecutive days. Spirometry and exhaled
breath collection was performed before and after 12 days of
treatment. Subjects completed also a questionnaire covering
respiratory symptoms, smoking habits, and information
about environmental and occupational exposures.
The protocol was approved by the Ethic Committee of
the University Hospital of Parma, and patients signed an
informed consent.
2.2. Subjects. This study enrolled two groups, twenty (20)
patients with alveolar pulmonary diseases—pneumoco-
niosis—(15 men and 5 women, aged 54–84) and twenty
two (22) patients with bronchial diseases (11 men and 11
women, aged 41–82). Patients received 12 days inhalation
treatment with salt-bromide-iodine water in Terme of
Monticelli (Parma), Italy. The pneumopathology of each
subject was ascertained according to standard diagnostic
tests with the recommendations of the American Thoracic
Society/European Respiratory Society (ATS/ERS) [11]. All
20 pneumoconiosis were recognized as occupational diseases
by former exposure to asbestos or crystalline silica dust and
granted by the Italian Workers’ Compensation Authority.
In order to evaluate the eﬀect of thermal water inhalation
on metallic elements present in the airways, the subgroup
of 21 patients with relevant smoking history (at least 10
pack/years) was earmarked. Smoking status was assessed
in terms of self-reported smoking history (cigarette/day,
pack/years). Ex-smokers were defined as those patients who
stopped smoking for at least six months. The exclusion
criteria for both groups were acute respiratory illness in
the three weeks preceding the study and the recent use
of medications (antihistamines, bronchodilators). Table 1
shows the main characteristics of the two groups. 17 healthy
subjects (4 men and 13 women, range aged 24–53) not
exposed to thermal water were recruited as controls for
quantification of anions in EBC samples.
2.3. Spirometry. Forced vital capacity (FVC), forced expi-
ratory volume (FEV1), FEV1/FVC ratio, peak expiratory
flow rate (PEFR), and forced expiratory flow 25–75% (FEF
25–75%) were measured using a KOKO spirometer (Sen-
sormedics Italia Srl, Milan, Italy), and the best of three values
were expressed as a percentage of the predicted normal value.
Measurements were obtained and evaluated in accordance
with the recommendations of the ATS/ERS [11].
2.4. Exhaled NO (eNO) Measurements. eNO was measured
by portable device composed with electrochemical sensor
(HypAir FENO, Sensormedics, Milan, Italy). The analyzer
was calibrated by the manufacturer with range from 100
to 1000 ppb, linearity error < 0.5%, and reproducibility of
±2.5 ppb adapted for online recording of NO concentration
in exhaled breath. HypAir FENO is enabled to measure the
eNO at multiple exhaled flow rates and calculates bronchial
and alveolar eNO concentration. It is possible to calculate
also three flow-dependent NO exchange parameters: airway
tissue nitric oxide concentration (Caw,NO), alveolar nitric
oxide concentration (CA,NO), and airway transfer factor (or
diﬀusing capacity) for nitric oxide (Daw,NO = Caw,NO −
CA,NO). We quantified the fractional nitric oxide concen-
tration at diﬀerent flow rates, 50mL/s (FENO50), 100mL/s
(FENO100), 150mL/s (FENO150), 350mL/s (FENO350), the
CA,NO, and the maximum total airway nitric oxide flux
(J′aw,NO) from Daw,NO. Subjects abstained from food and
caﬀeine intake for 2 h, smoking for 6 h, and alcohol for
12 h before the test. All exhaled NO measurements were
performed according to current ATS/ERS guidelines [12].
2.5. EBC Biomarkers. The transportable unit TURBO-
DECCS condenser (Medivac, Parma, Italy) was used for
EBC collection. Patients were asked to breath tidally through
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Table 1: Characteristic of the groups.
Subjects Gender Age BMI Smokers/Ex-smokers (N) Pack/years (PY)
Total (N = 42) M = 26; F = 16 70.8± 9.3 28.2± 4.5 7/18 23.5 (14.3–39.5)
Alveolar diseases (N = 20)
(i) Silicosis (N = 12) M = 10; F = 2 76.3± 5.0 27.2± 3.5 0/8 17 (5.8–37.3)
(ii) Asbestosis (N = 6) M = 3; F = 3 65.5± 9.9 26.6± 4.2 2/1 24 (1.4–68)
(iii) Silicoasbestosis (N = 2) M = 2; F = 0 69.5± 0.7 28.9± 0.7 0/1 —
Bronchial diseases (N = 22)
(i) Chronic bronchitis (N = 15) M = 7; F = 8 68.3± 9.3 30.3± 7.2 3/6 22.5 (14.5–70.3)
(ii) Asthma (N = 7) M = 4; F = 3 66.1± 11.6 27.8± 2.8 2/3 23.4 (17.1–50.5)
Smokers or ex smokers with PY > 10 (N = 21) M = 17; F = 4 70.4± 11.5 28± 3.3 7/14 25 (17–48.8)
Data presented as mean ± SD; SD: standard deviation or median (IQR); IQR: interquartile range.
the mouthpiece for 15 minutes through a two-way non-
rebreathing valve by which inspiratory and expiratory air is
separated and saliva is trapped. The temperature of the con-
denser was set at −5◦C, respecting all of the recommended
practical standards and anticontamination principles for
EBC collection published by ATS/ERS [13]. 1-2mL of EBC
samples were stored immediately at −80◦C and kept frozen
until analysis.
2.5.1. H2O2. H2O2 in EBCwasmeasured using a commercial
kit (Amplex Red Hydrogen Peroxide/Peroxidase assay kit,
Molecular Probes, Eugene, OR, USA). Briefly, 50 μL of
EBC was mixed with 50 μL of a solution containing 0.2
U/mL horseradish peroxidase (HRP), 100 μM 10-acetyl-
3,7-dihydroxyphenoxazine (Amplex Red reagent) and was
incubated for 30min at room temperature, protected from
light. H2O2 reacts with the Amplex Red reagent (1 : 1
stoichiometry) in the presence of HRP to produce highly
fluorescent resorufin. The amount of resorufin, as a measure
of the amount of H2O2, was determined spectrofluorimet-
rically using a Cary Eclipse fluorescence spectrophotometer
(Varian Inc., Palo Alto, CA, USA). H2O2 calibration curve
was composed with seven concentration levels (range 0–
5.0 μM).
2.5.2. Metals. EBC samples were sent, on dry ice, to the
Laboratory of Industrial Hygiene and Toxicology, University
Hospital of Brescia (Italy). The laboratory is certified for
analysis of metallic elements. EBC samples underwent
inductively coupled plasma-mass spectrometry (ICP-MS)
analysis on a Perkin Elmer ELAN DRC II instrument (Perkin
Elmer, Sciex, Canada) using an analytical technique for
total quantification with external calibration and reference
material. For each sample, two runs were performed (two
replicates each), one with dynamic reaction cell (DRC) and
one without DRC. We determined concentrations of the fol-
lowing elements: arsenic (As), barium (Ba), cadmium (Cd),
calcium (Ca), cobalt (Co), chromium (Cr), copper (Cu),
iron (Fe), mercury (Hg), manganese (Mn), molybdenum
(Mo), nickel (Ni), lead (Pb), selenium (Se), strontium (Sr),
tin (Sn), vanadium (V), and zinc (Zn); Cr and Fe were
determined by DRC using NH3 at a flow of 0.6mL/min.
The method accuracy was determined in natural water
standard reference materials (NIST 1640 from the National
Institute of Standard and Technology, Gaithersburg, MD
20899-1070). The coeﬃcients of variation (CV) ranged from
4% to 8% among series and from 6% to 12% between series.
The instrument was calibrated using standard solution at a
concentration of 10 μg/L (Multielement ICP-MS Calibration
Standard 3, Matrix per Volume: 5% HNO3 per 100mL,
Perkin Elmer Plus) including Al, As, Ba, Be, Bi, Ca, Cd,
Co, Cr, Cs, Cu, Fe, Ga, In, K, Li, Mg, Mn, Ni, Pb, Rb, Se,
Na, Ag, Sr, Ti, V, U. The limits of detection (LOD) were
determined on the basis of 3 SD of the background signal
and the following values (as μg/L) were obtained: 0.001 for
As and V; 0.002 for Cr, Mn, and Zn; 0.003 for Co; 0.004 for
Cs, Cu, Ni, Pb, and Sr; 0.005 for Ba,Mo, Fe, Hg, and Sn; 0.006
for Cd; 0.05 for Se; 1.0 for Ca.
2.5.3. Anions. The quantification of anions was performed
by ion exchange Dionex chromatography (ICS 2100, Dionex
Corporation, Sunnyvale, CA). One hundred μL for each
sample has injected manually. After separation on Dionex
Ion Pack AS19 4× 250mm column equipped with AG19 4×
50mm precolumn at 30◦C, the anions were quantitated by
conductance measurements. The temperature of conducto-
metric cell was set at 35◦C. The eluent was generated elec-
trolytically with potassium hydroxide. During each sample
run, the eluent concentration was increased along a linear
gradient of KOH. The suppressor was Dionex ASRS 300
4mm with current of 112 milli Ampere. The eluent flow rate
was 1mL/min in accordance with the recommendation from
the column manufacturer. The noise was 1 nS. The multian-
alytes standard solutions were prepared daily from a Dionex
stock solution. The limit of detection (LOD) for each anion
was formate 15 ppb, chloride 10 ppb, nitrite 10 ppb, nitrate
10 ppb, sulphate 10 ppb, and oxalate 5 ppb (ppb = μg/L).
2.6. Statistical Analysis. The data were statistically analyzed
using the SPSS software v.17.0 (SPSS inc., Chicago, IL, USA)
and a P value < 0.05 was always considered significant. The
distributions of all the variables were tested by means of the
Kolmogorov-Smirnov test: normally distributed variables are
expressed as mean values± SD, and not normally distributed
variables as median values with the IQR (25th and 75th
percentiles). Depending on the normality of variables, the
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Table 2: Eﬀect of 12 days thermal treatment with salt-bromide-iodine thermal water on lung function parameters.
Variables
Alveolar diseases Bronchial diseases
BT AT ∗P value BT AT ∗P value
FVC (L) 2.6± 0.8 2.8± 0.6 ns 2.5± 1.1 2.7± 1.0 ns
FEV1 (L) 2.0± 0.6 2.1± 0.6 ns 1.7± 0.8 1.9± 0.7 ns
FEV1/FVC (L) 0.73± 0.08 0.75± 0.07 ns 0.68± 0.12 0.69± 0.1 ns
PEFR (L/s) 5.1± 1.9 5.4± 1.9 ns 4.8± 1.7 5.1± 1.8 P < 0.01
FEF25−75% (L) 1.7± 0.7 1.8± 0.8 ns 1.2± 0.7 1.4± 0.8 ns
Data expressed as mean ± SD; SD: standard deviation; ∗Paired t-test; BT: before treatment; AT: after treatment; ns: not significant.
Student’s t-test for paired samples or the Wilcoxon rank sum
test was used to compare the data before and after treatment.
The EBC anion concentrations were compared before
and after inhalation of thermal salt-bromide-iodine water in
the group of patients with pneumopathologies and versus
controls by one-way ANOVA analysis of variance with Post
Bonferroni test for nitrates and by Kruskal-Wallis with post-
Dunn’s test for other anions. The bivariate linear correlations
between variables were reported as Rho of Spearman (ρ).
3. Results
Twenty patients with occupational pneumoconiosis and
twenty-two with bronchial diseases (asthma and chronic
bronchitis) were examined. Among 42 recruited subjects, 7
current smokers and 18 ex-smokers with PY of 23.5 (14.3–
39.5) were present, and subgroup of 21 patients with relevant
smoking history (at least 10 PY) and PY of 25 (17–48.8)
was distinguished. In 14 subjects, the airflow obstruction as
ratio between FEV1/FVC (<0.7) was found; the obstruction
was present in six patients with bronchial diseases and in
eight patients with alveolar diseases. Among the patients
with airway obstruction, two subjects were current smokers,
eight of them were ex-smokers and four patients were never
smokers.
3.1. Lung Function Parameters. Table 2 shows mean values
± SD (standard deviation) of lung function parameters
before and after 12 days of thermal treatment for both
groups of patients. All spirometric data have been found
higher after thermal treatment compared to baseline values,
but only mean PEFR value in bronchial diseases increased
significantly (4.8±1.7 versus 5.1±1.8; P < 0.01). In the group
of patients with airflow obstruction (N = 14) (Table 3),
the index FEV1/FVC increased significantly compared to
baseline value (0.6± 0.08 versus 0.65± 0.1; P < 0.05).
3.2. FENO and Flow-Dependent NO Parameters. There were
no significant diﬀerences for levels of FENO at diﬀerent flow
rates (50, 100, 150, 350) in both groups of patients before
and after thermal salt-bromide-iodine water inhalation, as
reported in Table 4. Also for maximum total airway nitric
oxide flux (J′aw,NO) and alveolar nitric oxide concentration
(CA,NO), there were no statistical diﬀerence.
3.3. H2O2-EBC. In the group of patients with alveolar
diseases, the H2O2-EBC concentrations before thermal
Table 3: Eﬀect of 12 days thermal treatment with salt-bromide-
iodine thermal water on lung function parameters in patients with
airflow obstruction (FEV1/FVC < 0.7).
Variables
Treatment ∗P value
BT AT
FVC (L) 2.5± 1.1 2.6± 0.9 ns
FEV1 (L) 1.7± 0.8 1.7± 0.7 ns
FEV1/FVC (L) 0.6± 0.08 0.65± 0.1 P < 0.05
PEFR (L/s) 4.3± 1.8 4.6± 1.4 ns
FEF25–75% (L) 0.9± 0.5 1.1± 0.6 ns
Data expressed as mean ± SD (standard deviation); ∗Paired t-test; BT:
before treatment; AT: after treatment; ns: not significant.
treatment were not significantly compared after inhalation
(0.29 (0.19–0.58) versus 0.28 (0.09–0.9), P = ns; Table 5). As
well, there were no significant changes in H2O2-EBC con-
centrations after 12 days of thermal treatment in group of
bronchial diseases (0.29 (0.18–0.58) versus 0.34 (0.13–0.91),
P = ns; ns = not significant, Table 5).
3.4. EBC Metals Concentrations in Subgroup of Patients
with Significant Smoking History. Concentrations of metals
quantified before and after treatment in EBC smokers and
ex smokers with significant smoking history (PY > 10)
are reported in Table 6. All metals concentrations in EBC
have not been significantly modified after thermal treatment
compared to baseline values.
3.5. EBC Anions. The concentrations of anions in patients
before and after inhalation of salt-bromide-iodine thermal
water versus controls are reported in Table 7. There was
no statistical diﬀerence before and after thermal treatment
for each anion. Regarding the EBC ionic composition, the
nitrate concentrations were found to be significantly higher
in patients before inhalation than in controls (1169.5 ±
510.8 versus 256.3 ± 171.2, P < 0.001) as well as in patients
after inhalation versus controls (1417.7 ± 375.0 versus
256.3 ± 171.2, P < 0.001), Figure 1. The contrary opposite
behaviour was observed for sulphate, where the sulphate
anion concentrations have been found significantly lower as
compared to controls, both before (10.0 (10.0–27.9) versus
(66.9 (24.6–117.9), P < 0.001) and after treatment (10.0
(10.0–24.3) versus (66.9 (24.6–117.9), P < 0.001). The
concentrations of anions were highly correlated one each
ISRN Pulmonology 5
Table 4: Eﬀect of 12 days treatment with salt-bromide-iodine thermal water on flow-dependent NO parameters (FENO50, FENO100,
FENO150, FENO350, J′aw,NO, CA,NO).
Variable
Alveolar diseases Bronchial diseases
BT AT #P value BT AT #P value
FENO50 (ppb) 25 (13.3–37.8) 26 (16.7–44.5) ns 24 (17–52) 20 (17–31) ns
FENO100 (ppb) 18 (14–28) 18.5 (12–22.8) ns 17 (12.5–24) 16 (11–26) ns
FENO150 (ppb) 12 (11.5–23.5) 11.5 (9.7–23.5) ns 15.5 (10–22) 12.5 (10.5–18.5) ns
FENO350 (ppb) 10 (6.5–10.5) 9 (5.5–12.8) ns ND ND ND
J′aw,NO (nL/min) 54.8 (35.7–112) 65 (37.8–92.2) ns 54.4 (35.8–80.6) 33.5 (24.0–73.8) ns
CA,NO (ppb) 6.6 (3.1–12.2) 6.2 (4–9.6) ns 7.4 (3.4–19.6) 9.4 (5–15.6) ns
Data expressed as median IQR; IQR: interquartile range; #Wilcoxon rank-sum test; BT: before treatment; AT: after treatment; FENO50: fractional nitric oxide
concentration at flow rate of 50mL/s; FENO100: fractional nitric oxide concentration at flow rate of 100mL/s; FENO150: fractional nitric oxide concentration
at flow rate of 150mL/s; FENO350: fractional nitric oxide concentration at flow rate of 350mL/s; J′aw,NO: maximum total airway nitric oxide flux; CA,NO:
alveolar nitric oxide concentration; ND: not determined; ns: not significant.
Table 5: Eﬀect of 12 days treatment with salt-bromide-iodine thermal water on H2O2-EBC concentrations.
Variable
Alveolar Bronchial
BT AT #P value BT AT #P value
H2O2 (μM) 0.29 (0.19–0.58) 0.28 (0.09–0.9) ns 0.29 (0.18–0.58) 0.34 (0.13–0.91) ns
Data expressed as median (IQR); IQR: interquartile range; #Wilcoxon rank sum test; BT: before treatment; AT: after treatment; ns: not significant.
Table 6: Eﬀect of 12 days treatment with salt-bromide-iodine
thermal water on EBC metals concentrations.
Metals BT (mg/L) AT (mg/L) P value
Al 1.36 (0.73–2.2) 1.4 (1.1–2.3) #ns
Mn 0.38 (0.28–0.69) 0.5 (0.32–1.0) #ns
Co 0.02 (0.006–0.06) 0.02 (0.006–0.1) #ns
Sr 0.56± 0.09 0.57± 0.06 ∗ns
Ba 0.32± 0.08 0.33± 0.06 ∗ns
Ca 249 (38.5–394) 270 (67–348) #ns
Pb 0.043± 0.01 0.058± 0.01 ∗ns
I 0.21± 0.07 0.3± 0.1 ∗ns
Cu 1.24± 0.2 1.25± 0.3 ∗ns
Si 50 (28.8–69.8) 32 (15–62) #ns
Fe 2.5 (1.2–7.2) 3.1 (1.5–6.3) #ns
Cr 1.2± 0.4 1.5± 0.5 ∗ns
Ni 1.0 (0.3–5.8) 1.0 (0.85–6.1) #ns
Rb 0.09± 0.01 0.12± 0.02 ∗ns
Data expressed as median (IQR); IQR: interquartile range or mean ± SE;
SE: standard error; #Wilcoxon rank sum test; ∗Paired t-test; BT: before
treatment; AT: after treatment; ns: not significant.
other. There was a significant correlation between formate
concentrations before inhalation with hydrogen peroxide
before inhalation, ρ = 0.45, P < 0.05 (data not shown).
4. Discussion
The positive eﬀect of the thermal water inhalation is
generally based on the patients’ subjective sense of wellbeing,
whereas more diﬃcult is to measure or quantify clinical
improvements. In our study, we assessed the eﬀects of
Table 7: EBC anions concentrations (ppb = μg/L) for patients with
pneumopathologies before and after inhalation of salt-bromide-
iodine thermal water versus controls.
Anion
Treatment
Controls
BT AT
Formate
101.1
(55.1–231.2)
160.3
(85.6–208.0)
93.4
(69.3–322.2)
Chloride
193.3
(88.1–271.8)
227.4
(130.4–275.2)
101.6
(53.6–188.9)
Nitrite
47.1
(21.1–141.7)
40.6
(30.3–124.9)
67.5
(21.9–156.8)
Nitrate 1169.5 ± 510.8 1417.7 ± 375.0  256.3 ± 171.2∗∗∗
Sulphate
10.0
(10.0–27.9)
10
(10.0–24.3)
ϕ66.9∗∗∗
(24.6–117.9)
Oxalate
39.6
(34.3–48.7)
44.1
(39.7–52.1)
ND
Data reported as median values (IQR); IQR: interquartile range, only for
nitrate as mean values ± SD (SD: standard deviation); one-way ANOVA
analysis of variance with Post Bonferroni test, P < 0.001 ∗∗∗both controls
versus BT and controls versus AT; ϕKruskal-Wallis with Dunn’s post-test,
P < 0.001 ∗∗∗both controls versus BT and controls versus AT; BT: before
treatment; AT: after treatment; ND: not determined.
salt-bromide iodine thermal water inhalation on lung func-
tions parameters and on eﬀect biomarkers. To the best of
our knowledge, this is the first study that has used FENO
measurement at multiple exhaled flow rates in exhaled
breath, metals, and anions quantification in EBC, in order
to investigate the biochemical changes airways in patients
with bronchial and alveolar pneumopathologies who receive
the inhalation thermal treatment with salt-bromide-iodine
water. Most of our patients, who receive thermal treatment
every year, have confirmed the subjective improvement and
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Figure 1: EBC nitrate concentrations for patients before and after
inhalation of thermal salt-bromide-iodine water versus controls.
The horizontal lines represent mean values. Statistical diﬀerences
between three groups were calculated by one-way ANOVA analysis
of variance with Bonferroni’s post-test.
sense of “easier breathing,” which usually appear in the next
weeks after the end of the treatment. The PEF value in
patients with bronchial diseases have increased significantly
(Table 2), whereas other spirometric parameters in both
bronchial and alveolar diseases have been found increased
not significant after treatment. Pellegrini et al. [5] have
found not significantly changes in lung function after 2
weeks of treatment with salt-bromide-iodine thermal water
in COPD patients. In our study, when we analyzed the group
of patients with objective airflow obstruction (FEV1/FVC <
0.7), the index FEV1/FVC increased significantly after ther-
mal treatment compared to baseline values before (Table 3),
but the reliability of this improvement is debatable due to
the small number of subjects (N = 14). One of the working
hypothesis was that treatment with salt-bromide-iodine
water was able to replace or increase GSH, reducing oxidative
stress in lung disorders associated with inflammation, deple-
tion of HS groups and production of ROS [14–16]. Recent
studies have demonstrated evidences on anti-inflammatory
and antioxidative eﬀect of thermal water [1, 17–19]. Samples
of exhaled breath are suitable medium to study biomarkers
of pulmonary inflammation and oxidative stress, which may
be sensitive endpoints for identifying biochemical changes
in the airways after specific treatment [20]. FENO values
after thermal treatment remained similar to those measured
before inhalation (Table 4). In our study, the treatment
with thermal water has not changed significantly H2O2-
EBC concentrations (Table 5), and the working hypothesis
of antioxidant eﬀect of thermal water was not confirmed.
Another working hypothesis was that thermal water was
able to modify pulmonary concentration of heavy toxic
metals of cigarette smoke, either through an improvement
in rheological characteristics of the mucus or improving
individual detoxifying capacity. It can be speculated that
sulphur components can detoxify toxic elements (e.g., Hg,
Cd and Pb) making these metals soluble in water and
improving their clearance. The toxic metals were detectable
in EBC and have been proposed as a suitable biomarkers
of exposure as a means of assessing the target tissue dose
of carcinogenic and pneumotoxic substances from tobacco
smoke [21]. Currently, the studies on metals in EBC
after specific treatment are not available and we can only
speculate about positive eﬀect of thermal water related to
supplementation of SH groups which should accelerate the
excretion rate of the mobilized metals. Anyway, the results
of our study in subjects with significant smoking history
(PY > 10) have not confirmed this hypothesis. All metals
analyzed in EBC before and after treatment have not shown
significant diﬀerences (Table 6). Moreover, we have used
ion chromatography to quantify the concentrations of six
anions in EBC. This technique yields highly reproducible
results with a low detection limit. Only few works in the
literature have used high sensitivity ion chromatography to
quantify anions composition in EBC [22]. Greenwald et
al. [23] quantified EBC anions before and after exercise in
adolescent healthy athletes and did not find any influence
on EBC anions composition. In our study we did not find
any diﬀerence in anions EBC concentrations before and
after water thermal treatment in patients with bronchial
and alveolar pneumopathologies. Except for nitrites and
sulphates, anions EBC concentrations after treatment were
higher than before, but not significant (Table 7). Greenwald
et al. [24] found that EBC formate concentrations were
significantly higher in the EBC of children with asthma than
in those without asthma. For the first time, the presence
of a respiratory disorder such as asthma made a diﬀerence
in anions EBC composition. Also in our study we reported
that patients with pneumopathologies had nitrates EBC
concentrations higher compared to controls (Figure 1) and
the contrary opposite behaviour was observed for sulphate
concentrations (Table 7). The increased EBC nitrate levels
were expected on the basis of the known enhanced pro-
duction of nitric oxide oxidative products into airways of
diseased subjects [13]. Recently, Malinovschi et al. [22]
confirmed that EBC nitrates concentration is a biomarker
significantly related to asthma control. We speculate that
the reduced EBC sulphate concentrations in patients might
be linked to a depletion of sulfhydryl- (SH-) containing
molecules into airways, which may occur in patients with
lung diseases [25].
5. Conclusions
There is no evidence that thermal water inhalation aﬀects the
inflammation and oxidative stress in the airways and modify
pulmonary concentration of smoking-related biomarkers
after 12 days treatment. Probably, the improvement of func-
tional parameters and the modification of exhaled biomark-
ers are not detectable immediately within 12 days of treat-
ment, and repeated follow-up examination several weeks
after the end of thermal water inhalation could be important
for a better understanding of possible long term eﬀects.
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